Effects of silymarin, a natural hepatoprotector, in periparturient dairy cows

Silymarin, a natural acknowledged hepatoprotector used in humans to treat liver diseases, has been tested in dairy cows during peripartum, a period during which animals are subject to subclinical fatty liver. Ten grams of silymarin (76% pure extract consisting in flavonolignans, taxifolin, and other trace compounds) per day, was administered as a water suspension by an oral drench to 15 cows from d 10 before expected calving to 15 d after calving. Milk production was measured, and colostrum, milk, and blood samples were analyzed during the experimental period. Treated animals showed the peak of milk production at 55 ± 1.85 d after calving, 1 wk before the control group (62 ± 3.27d); the average peak production was 41.6 ± 1.05 kg for the treated group vs. 39.1 ± 1.44 kg for the control; the treated animals maintained a greater milk production than control cows throughout lactation (9922.1 ± 215.7 vs. 9597.8 ± 225.4 kg). Milk composition was unaffected by treatment. No silymarin residues were detected in colostrum and all milk samples. After calving, body condition score (BCS) decrease was greater for control compared with treated cows. Glucose, urea, triglycerides (TG), total cholesterol, β-hydroxibutyrate (BHBA), and γ-glutamyl transferase (GGT) in plasma were unaffected by treatment. Plasma nonesterified fatty acids (NEFA) on d - 7 were higher in treated cows compared with the control group (741 vs. 181 μmol/L). From this evidence, it is possible to conclude that silymarin beneficially affected lactation performances and body condition of treated animals. Blood and milk parameters do not indicate any adverse effects of feeding this natural compound.